Exelixis Accounts Payables 2011-2026 | EXEL

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Exelixis

2026	2025	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
29.6 M	38.2 M	33.8 M	32.7 M	24.3 M	11.6 M	-	10.9 M	9.58 M	6.56 M	6.4 M	6.41 M	9.34 M	4.4 M	1.96 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
38.2 M	1.96 M	16.1 M

Quarterly Accounts Payables Exelixis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
25.3 M	25.8 M	42.8 M	38.2 M	59.3 M	28.7 M	26.1 M	33.8 M	26.4 M	26 M	32.6 M	32.7 M	30.6 M	20 M	17.3 M	24.3 M	24.3 M	20.4 M	13.8 M	11.6 M	47.9 M	9.1 M	15.3 M	-	8.35 M	12.3 M	9.75 M	10.9 M	10.9 M	10.9 M	10.9 M	9.58 M	9.58 M	9.58 M	9.58 M	6.56 M	3.96 M	6.56 M	6.56 M	6.4 M	6.4 M	6.4 M	6.4 M	6.41 M	6.41 M	6.41 M	6.41 M	9.34 M	9.34 M	9.34 M	9.34 M	4.4 M	4.4 M	4.4 M	4.4 M	1.96 M	1.96 M	1.96 M	1.96 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
59.3 M	1.96 M	15.2 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
I-Mab IMAB	570 M	-	-	$ 866 M	China
AlloVir ALVR	1.28 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	1.58 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	1.74 M	-	-	$ 8.42 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 2.92	-0.34 %	$ 6.35 B	Israel
Amphastar Pharmaceuticals AMPH	32.6 M	$ 20.37	-2.4 %	$ 952 M	USA
Acorda Therapeutics ACOR	13.4 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	1.61 M	-	-	$ 86.2 M	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
Celldex Therapeutics CLDX	1.18 M	$ 32.24	-4.1 %	$ 2.14 B	USA
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	21.2 M	$ 1.4	-0.71 %	$ 360 M	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
Aptinyx APTX	724 K	-	-39.0 %	$ 4.57 M	USA
Aquestive Therapeutics AQST	29.9 M	$ 4.08	-2.16 %	$ 436 M	USA
Aravive ARAV	8.76 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	12.5 M	$ 24.21	-1.47 %	$ 3.08 B	USA
AIkido Pharma AIKI	611 K	-	1.93 %	$ 17.4 M	USA
Autolus Therapeutics plc AUTL	3.08 M	$ 1.49	1.36 %	$ 397 M	Britain
Aptose Biosciences APTO	2.91 M	-	-45.71 %	$ 1.2 M	Canada
Cidara Therapeutics CDTX	3.61 M	-	-	$ 1.41 B	USA
AVROBIO AVRO	27 K	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	10.6 M	$ 2.55	-0.78 %	$ 16 M	USA
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
Brainstorm Cell Therapeutics BCLI	7.07 M	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	479 M	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	1.28 M	-	0.23 %	$ 488 M	USA
Akari Therapeutics, Plc AKTX	8.77 M	$ 3.83	-2.3 %	$ 258 B	Britain
Allena Pharmaceuticals ALNA	1.03 M	-	3.16 %	$ 1.9 M	USA
Baudax Bio BXRX	3.93 M	-	0.59 %	$ 63 K	USA
Alpine Immune Sciences ALPN	4.29 M	-	-	$ 2.17 B	USA
Cabaletta Bio CABA	6.64 M	$ 3.13	-1.26 %	$ 315 M	USA